Abbott Korea launches tulobuterol patch

Abbott Korea said it has launched tulobuterol patch (brandname: Hokunalin) for the treatment of asthma.

Tulobuterol patch, which was developed to address nocturnal symptoms and maintenance of lung function in asthmatic patients, have a lower risk of systemic side effects than oral formulations with a long duration of action (24 h) on the local site, the company says. Its once-daily easier ap...